All Updates

All Updates

icon
Filter
Partnerships
Eli Lilly collaborates with OpenAI to overcome antimicrobial resistance using AI
AI Drug Discovery
Jun 25, 2024
This week:
Funding
Third Arc Bio raises USD 165 million in Series A funding to advance oncology and autoimmunity clinical programs
Precision Medicine
Yesterday
Partnerships
BostonGene collaborates with Sylvester Comprehensive Cancer Center to validate blood- and bone marrow-based assays for hematological cancers
Precision Medicine
Yesterday
Partnerships
Pinetree Therapeutics enters license agreement with AstraZeneca for preclinical EGFR degrader candidate
Precision Medicine
Yesterday
Partnerships
Oxford Nanopore Technologies and Plasmidsaurus partner to transform plasmid sequencing market
Precision Medicine
Yesterday
Partnerships
Altair partners with University of Nottingham to develop aerospace digital twin project
Digital Twin
Yesterday
Product updates
Tompkins Robotics launches ‘tSortPost,’ a flexible and scalable solution for parcel sorting
Logistics Tech
Yesterday
Partnerships
Kodiak Robotics partners with Atlas Energy Solutions to equip high-capacity trucks with autonomous technology
Truck Industry Tech
Yesterday
Funding
Plum Fintech raises GBP 16 million in Series B funding to expand product offerings
Retail Trading Infrastructure
Yesterday
Funding
Plum Fintech raises GBP 16 million in Series B funding to expand product offerings
Financial Wellness Tools
Yesterday
Management news
Akselos appoints Claus Reimers as CPTO
Digital Twin
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 25, 2024

Eli Lilly collaborates with OpenAI to overcome antimicrobial resistance using AI

Partnerships

  • Eli Lilly has partnered with AI company OpenAI to develop novel antimicrobials targeting drug-resistant pathogens. The terms and conditions of the agreement have not been disclosed.

  • Through this partnership, Eli Lilly will leverage OpenAI's GenAI technology to fast-track the discovery and production of novel therapeutics to address antimicrobial resistance (AMR). The collaborative effort aims to use GenAI to accelerate drug discovery and develop custom, purpose-built technologies to target drug-resistant pathogens.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.